Literature DB >> 16120757

Suppressor of cytokine signalling 1 in lymphocytes regulates the development of intestinal inflammation in mice.

K Inagaki-Ohara1, A Sasaki, G Matsuzaki, T Ikeda, M Hotokezaka, K Chijiiwa, M Kubo, H Yoshida, Y Nawa, A Yoshimura.   

Abstract

BACKGROUND AND AIMS: Imbalance between pro- and anti-inflammatory cytokines produced by intestinal T cells induces inflammatory bowel diseases (IBD). However, the importance of regulation of cytokine signalling in IBD has not been fully clarified. We have demonstrated that suppressor of cytokine signalling 1 (SOCS1) is expressed in inflamed tissues in an experimental colitis model. In the present study, we investigated the role of SOCS1 in colitis models to clarify the mechanism of IBD development.
METHODS: Intestinal T cells in transgenic mice expressing high levels of SOCS1 in lymphocytes (SOCS1Tg mice) were characterised by flow cytometric analysis and cytokine production from intestinal T cells was determined by ELISA. 2,4,6-Trinitrobenzene sulphonic acid (TNBS) induced colitis was induced in SOCS1Tg mice and severity was compared with control littermates by measurement of survival rates. Intracellular signalling was assessed by western blotting analysis.
RESULTS: SOCS1Tg mice developed colitis spontaneously with age. Young SOCS1Tg mice less than 15 weeks of age, before the onset of colitis, were susceptible to TNBS induced colitis. Intestinal T cells of SOCS1Tg mice showed increased interferon gamma and tumour necrosis factor alpha production and decreased transforming growth factor beta production. Expression of cytotoxic T lymphocyte associated antigen 4 (CTLA-4), a negative regulator of T cell activation, in SOCS1Tg mice was severely impaired at the protein level although mRNA levels of CTLA-4 in SOCS1Tg mice were comparable with those in control mice.
CONCLUSIONS: Our data suggest that SOCS1 plays an important role in the regulation of colitis by controlling intestinal T cell activation mediated through CTLA-4 expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16120757      PMCID: PMC1856512          DOI: 10.1136/gut.2004.062653

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

1.  SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase.

Authors:  K i Ohya; S Kajigaya; Y Yamashita; A Miyazato; K Hatake; Y Miura; U Ikeda; K Shimada; K Ozawa; H Mano
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

2.  Structure and function of a new STAT-induced STAT inhibitor.

Authors:  T Naka; M Narazaki; M Hirata; T Matsumoto; S Minamoto; A Aono; N Nishimoto; T Kajita; T Taga; K Yoshizaki; S Akira; T Kishimoto
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

3.  A new protein containing an SH2 domain that inhibits JAK kinases.

Authors:  T A Endo; M Masuhara; M Yokouchi; R Suzuki; H Sakamoto; K Mitsui; A Matsumoto; S Tanimura; M Ohtsubo; H Misawa; T Miyazaki; N Leonor; T Taniguchi; T Fujita; Y Kanakura; S Komiya; A Yoshimura
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

4.  Control of B cell development by Ras-mediated activation of Raf.

Authors:  B M Iritani; K A Forbush; M A Farrar; R M Perlmutter
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

5.  A family of cytokine-inducible inhibitors of signalling.

Authors:  R Starr; T A Willson; E M Viney; L J Murray; J R Rayner; B J Jenkins; T J Gonda; W S Alexander; D Metcalf; N A Nicola; D J Hilton
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

6.  Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.

Authors:  I J Fuss; M Neurath; M Boirivant; J S Klein; C de la Motte; S A Strong; C Fiocchi; W Strober
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

7.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

8.  A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells.

Authors:  F Powrie; J Carlino; M W Leach; S Mauze; R L Coffman
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

9.  CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation.

Authors:  A Suzuki; T Hanada; K Mitsuyama; T Yoshida; S Kamizono; T Hoshino; M Kubo; A Yamashita; M Okabe; K Takeda; S Akira; S Matsumoto; A Toyonaga; M Sata; A Yoshimura
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

10.  Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance.

Authors:  M F Neurath; I Fuss; B L Kelsall; D H Presky; W Waegell; W Strober
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Animal models of inflammatory bowel disease: a review.

Authors:  Nidhi Goyal; Ajay Rana; Abhilasha Ahlawat; Krishna Reddy V Bijjem; Puneet Kumar
Journal:  Inflammopharmacology       Date:  2014-06-07       Impact factor: 4.473

Review 2.  Gender differences, aging and hormonal status in mucosal injury and repair.

Authors:  Irina Grishina; Anne Fenton; Sumathi Sankaran-Walters
Journal:  Aging Dis       Date:  2014-04-01       Impact factor: 6.745

3.  Interleukin-17A is required to suppress invasion of Salmonella enterica serovar Typhimurium to enteric mucosa.

Authors:  Hirokazu Mayuzumi; Kyoko Inagaki-Ohara; Catherine Uyttenhove; Yuko Okamoto; Goro Matsuzaki
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

4.  SOCS proteins in development and disease.

Authors:  Monique C Trengove; Alister C Ward
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

Review 5.  Genetically engineered mouse models for studying inflammatory bowel disease.

Authors:  Atsushi Mizoguchi; Takahito Takeuchi; Hidetomo Himuro; Toshiyuki Okada; Emiko Mizoguchi
Journal:  J Pathol       Date:  2015-11-14       Impact factor: 7.996

6.  Clinical significance of mucosal suppressors of cytokine signaling 3 expression in ulcerative colitis.

Authors:  Yoshihiro Miyanaka; Yoshitaka Ueno; Shinji Tanaka; Kyoko Yoshioka; Tsuyoshi Hatakeyama; Masaru Shimamoto; Masaharu Sumii; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

Review 7.  Inflammatory bowel disease: review from the aspect of genetics.

Authors:  Shunji Ishihara; M M Aziz; Takafumi Yuki; Hideaki Kazumori; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

8.  Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15(-) Crohn's disease patients.

Authors:  Ana Márquez; Jezabel Varadé; Gema Robledo; Alfonso Martínez; Juan Luis Mendoza; Carlos Taxonera; Miguel Fernández-Arquero; Manuel Díaz-Rubio; María Gómez-García; Miguel Angel López-Nevot; Emilio G de la Concha; Javier Martín; Elena Urcelay
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

9.  γδ T cells play a protective role during infection with Nippostrongylus brasiliensis by promoting goblet cell function in the small intestine.

Authors:  Kyoko Inagaki-Ohara; Yukiko Sakamoto; Taeko Dohi; Adrian L Smith
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

10.  Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein.

Authors:  Li-Fan Lu; To-Ha Thai; Dinis Pedro Calado; Ashutosh Chaudhry; Masato Kubo; Kentaro Tanaka; Gabriel B Loeb; Hana Lee; Akihiko Yoshimura; Klaus Rajewsky; Alexander Y Rudensky
Journal:  Immunity       Date:  2009-01-16       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.